COMPANY

ADvantage Therapeutics

HQ: Miami, FL source · advantagetherapeutics.com ↗ · Southeast

ADvantage Therapeutics is developing therapeutics to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). From company website Source · Oct 12, 2026

Keywords:

Location: Miami, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

2NIH grants

Funding and NIH signals

NIH award NIH awarded $1.25M (SBIR Phase II 5R44AG091827-02, continuation, notice Jun 3, 2026). NIH RePORTER 5R44AG091827-02 (Jun 3, 2026)
Evidence (1 event)
- Jun 3, 2026 · NIH RePORTER 5R44AG091827-02
  Organization: ADVANTAGE THERAPEUTICS, INC; City/State: MIAMI, FL; Project number: 5R44AG091827-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1249368; Administering IC: National Institute on Aging; Project title: AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 26, 2025 Grant Government grant: $2.5M (total, as published), announced Sep 26, 2025. Source: company release on GlobeNewswire. source ↗

Funding

Last 2 years.

Sep 26, 2025 Government grant: $2.5M (total, as published), announced Sep 26, 2025. Source: company release on GlobeNewswire. source ↗

NIH awards 2

Annual award amounts. Total $2.5M.

Jun 3, 2026 NIH award 5R44AG091827-02 FY2026: $1,249,368 awarded for that fiscal year; activity R44 (SBIR); PI ABRAHAM, CARMELA R; recipient as written: ADVANTAGE THERAPEUTICS, INC, MIAMI, FL. AD04 disease-modifying drug for Alz source ↗
Sep 18, 2025 NIH award 1R44AG091827-01 FY2025: $1,249,957 awarded for that fiscal year; activity R44 (SBIR); PI ABRAHAM, CARMELA R; recipient as written: ADVANTAGE THERAPEUTICS, INC, MIAMI, FL. AD04 disease-modifying drug for Alz source ↗